VEGFR2 selective residue flexibility enriches AutoDock Vina docking results
VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) is a recognized anti-cancer protein target with already one known inhibitor, soranefib, in the market for therapeutic use.1 Protein-ligand docking tools can be used in order to find potential new VEGFR2 inhibitors. However, the quality of dockin...
| Main Author: | |
|---|---|
| Other Authors: | , , |
| Format: | conferenceObject |
| Language: | eng |
| Published: |
2011
|
| Online Access: | http://hdl.handle.net/10198/6035 |
| Country: | Portugal |
| Oai: | oai:bibliotecadigital.ipb.pt:10198/6035 |